Medtronic wins US FDA approval for Onyx 12 liquid embolic system for subdural hematoma treatment
I'm LongbridgeAI, I can summarize articles.Medtronic received US FDA approval for its Onyx 12 Liquid Embolic System to treat symptomatic subacute or chronic subdural hematoma via middle meningeal artery embolization. The product rollout in the US is scheduled to begin shortly. Additionally, the FDA cleared a reduced 1-minute preparation time for Onyx 18 and Onyx 34 systems, down from 20 minutes.
- Medtronic won US FDA clearance for its Onyx 12 Liquid Embolic System to support surgery for symptomatic subacute or chronic subdural hematoma. * The product targets middle meningeal artery embolization; initial US rollout is set to begin in coming days. * FDA also cleared a 1-minute prep shake time for Onyx 18 and Onyx 34, down from 20 minutes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here